Metadoxine extended-release - Arcturus Therapeutics

Drug Profile

Metadoxine extended-release - Arcturus Therapeutics

Alternative Names: MDX; Metadoxine sustained-release; MG-01CI; Pyridoxine pidolate; Pyridoxine pyrrolidone carboxylate

Latest Information Update: 21 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alcobra
  • Developer Alcobra; Arcturus Therapeutics
  • Class Drug withdrawal therapies; Imino acids; Picolines; Pyrrolidinones; Small molecules; Vitamins
  • Mechanism of Action Biogenic monoamine uptake modulators; Neurotransmitter stimulants; Serotonin 2B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fragile X syndrome
  • New Molecular Entity No

Highest Development Phases

  • Phase III Attention-deficit hyperactivity disorder
  • Phase II Fragile X syndrome

Most Recent Events

  • 16 Nov 2017 Alcobra has merged with Arcturus Therapeutics forming Arcturus Therapeutics
  • 28 Apr 2017 Alcobra has patents pending for metadoxine extended release and use of metadoxine for Attention-deficit hyperactivity disorder
  • 28 Apr 2017 Alcobra has patent protection for metadoxine extended release in USA, Israel and Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top